RNA Formulation Videos

1. Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles 4/25/2024

   The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?

2. R&D & CMC Priorities For LNPs Beyond Cell-Specific Delivery 12/4/2024

   It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches.

3. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

   mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

4. RNA Vaccine Development To Phase I 4/14/2022

   Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.

5. Q&A On LNP Cell-Specific Delivery 11/28/2022

   In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.

6. Next-Generation RNA Modality Supply Considerations

   Together, Life Edit Therapeutics’ April Sena and Sanofi’s Troiano share their perspectives on raw material quality & IP-related considerations for managing the supply chain for next-generation RNA modalities.

7. RNA-LNP Manufacturing Technology Delivering Transformative Medicines 10/13/2022

   NxGen™ microfluidic technology enables controlled and precise assembly of high-quality, uniform LNPs, ensuring reproducible scale-up of RNA-LNPs while maximizing drug loading and particle quality.

8. mRNA's Future Beyond The COVID Vaccines 11/28/2022

   In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, unpack which learnings can be adapted from ASO-LNPs to mRNA/LNPs and from mRNA vaccines to mRNA therapeutics. They also touch upon which learnings cannot be neatly carried over from these previous success stories.

9. The Next Frontier In mRNA: Modular Manufacturing For Scalable RNA-LNP Therapies 1/29/2025

   Explore constructing a modular RNA-LNP GMP facility using Cytiva's FlexFactory™ process train in a KUBio™ environment to scale RNA-LNP therapies.

10. The Pre-IND "Diaries": What Can mRNA Makers Expect From Early FDA Engagement? 5/10/2024

    Nutcracker Therapeutics’ Oreanna Thomas shares her takeaways from a pre-IND meeting for one of the company’s mRNA therapeutic candidates.